Our patient presented several risk factors (ESRD, female gender, history of obesity, diabetes mellitus, hyperparathyroidism, hyperphosphatemia and treatment with acenocoumarol and vitamin D receptor activator), so that we acted on those that could be modified pharmacologically. This evidence concerns the gene VDR and hyperparathyroidism.